Аннотация
Инвазивный аспергиллёз — распространённое осложнение у детей с гемобластозами. Для данного микоза характерны тяжесть клинического течения и высокая атрибутивная летальность. При лечении инвазивного аспергиллёза обычно используют монотерапию одним из системных антимикотиков. В последние годы появились сообщения об эффективном применении комбинации из двух различных противогрибковых средств. Авторы анализируют собственный опыт использования комбинации каспофунгина и вориконазола для лечения инвазивного аспергиллеза у ребёнка с гемобластозом, а также приводят данные литературы.
-
1.
Abbasi S., Shener J., Hughes W., et al. Aspergillosis in children with cancer: 34-year experience. Clin Infect Dis 1999; 29:1210.
-
2.
Denning D. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
-
3.
Patterson T., Kirkpatrick W., White M., et al. Invasive aspergillosis – disease spectrum, treatment practices, and outcomes. Medicine 2000; 79:250-60.
-
4.
Gilbert D., Moellering R., Epiopoulos G., Sande M., editors. The Sanford guide to antimicrobial therapy (thirty-sixth edition). USA; 2006.
-
5.
Steinbach W. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005; 5:203-10.
-
6.
Ascioglu S., Rex J., Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an internation consensus. Clin Infect Dis 2002; 34:7-14.
-
7.
Перечень основных методов и критериев диагностики микозов. Климко Н.Н., Васильева Н.В., Елинов Н.П. и др. - СПб.:00, 2001.-24 с.
-
8.
Patterson T., Kirkpatrick W., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000; 79:250-60.
-
9.
Steinbach W. Combination antifungal therapy for invasive aspergillosis - Is it indicated? Med Mycol 2006;44:373-82.
-
10.
Jeu L., Piacenti F., Lyakhovetskiy A., et al. Voriconazole. Clin Ther 2003; 25:1321-81.
-
11.
Wong-Beringer A., Jacobs R., Guglielmo B. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27:603-18.
-
12.
Patterson T. Treatment of invasive aspergillosis: polyenes, echinocandins, or azoles? Med Mycol 2006; 44:357-62.
-
13.
Groll A., Walsh T. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10:1545-58.
-
14.
Deresinski S., Stevens D. Caspofungin. Clin Infect Dis 2003; 36:1445-57.
-
15.
Lewis R., Kontoyiannis D. Rationale for combination antifungal therapy. Pharmacotherapy 2001; 21:149-164.
-
16.
Antoniadou A., Kontoyiannis D. Status of combination therapy for refractory mycoses. Curr Opin Infect Dis 2003; 16:539-45.
-
17.
Marr K. Combination antifungal therapy: where are we now and where are we going? Oncology 2004; 18:24-9.
-
18.
Steinbach W., Stevens D., Denning D. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37:188-224.
-
19.
Nivoix Y., Zamfir A., Lutun P., et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006; 52:67-74.
-
20.
Kontoyiannis D., Hachem R., Lewis R., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-9.
-
21.
Aliff T., Maslak P., Jurcic J., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-32.
-
22.
Marr K., Boeckh M., Carter R., et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
-
23.
Singh N., Limaye A., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
-
24.
Cesaro S., Toffolutti T., Messina C., et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004; 73:505.
-
25.
Rosen-Wolff A., Koch A., Friedrich W., et al. Successful elimination of an invasive Aspergillus nidulans lung infection by voriconazole after failure of a combination of caspofungin and liposomal amphotericin B in a boy with chronic glaucomatous disease. Pediatr Infect Dis J 2004; 23:584-6.
-
26.
Schuster F., Moelter C., Schmid I., et al. Successful antifungal combination therapy with voriconazole and caspofungin. Pediatr Blood Cancer 2005; 44:682-5.
-
27.
Elanjikal Z., Sorensen J., Schmidt H., et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 2003; 22:653-6.